Eve Medical is as an up and coming technology trend to watch in women's health.
Versant Ventures Announces Milestone with Recent Northern Biologics and BlueRock Therapeutics Deals
TORONTO & MONTREAL & VANCOUVER, British Columbia December 19, 2016 -Versant Ventures today announced that Toronto-based portfolio company Northern Biologics Inc. has executed a transformational deal that expands its pipeline and financial resources, bringing commitments to Versant’s Canadian biotech portfolio to over CAD$500 million.
MDCC Website Relaunched
On December 15 MDCC re-launched their website!
Click here to check out the new website
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
LEVERKUSEN, Germany and BOSTON and NEW YORK and TORONTO and KYOTO, Japan, Dec. 12, 2016 - Bayer AG and Versant Ventures today announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to develop best-in-class induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading platform. BlueRock Therapeutics will be led by a world-class team and has assembled its platform through a series of strategic partnerships with academia and industry.
Call for Innovations: Canadian Centre for Aging and Brain Health Innovation (CC-ABHI)
The Industry Innovation Partnership Program (I2P2) program will enable successful applicant companies worldwide, to test and validate their technology so as to obtain the evidence needed to successfully market their product into the seniors’ care and brain health marketplace.
Applicants must have a mature product or service that they would like to test with older adults at a North American trial partner site. I2P2 will co-invest up to $600,000 (CAD) to fund a trial of the applicant company’s innovative product or service. CC-ABHI will provide 50% of the project costs to the trial partner site to work with the company to test and validate the company’s product or service.
Expressions of Interest are due by 5 pm on December 9, 2016
Shortlisted applicants invited to complete an application form by December 23, 2016.
Final application forms are due by 5 pm on January 12, 2017 (EST).
CCAB contact:
Alisha Tharani | Manager, Strategic Partnerships
Canadian Centre for Aging and Brain Health Innovation
T. 416-785-2500 ext. 6429 | Atharani@baycrest.org | www.ccabhi.com
Proteocyte Diagnostics' Straticyte Receives Further NRC-IRAP Support
Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia
Vancouver and Toronto, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI).
Synaptive Medical and General Atlantic Announce Strategic Partnership
TORONTO and NEW YORK (November 3, 2016) — Synaptive Medical, a leading medical device and technology company that pursues connections to transform the process of care, announced today that General Atlantic, a global growth equity firm, has made a strategic investment in the company. With over 35 years of experience investing in 250 growth companies and deep expertise in the healthcare and technology sectors, General Atlantic partners with entrepreneurs and management teams around the world to help them accelerate growth and become market leaders.
IT’S A START Pitch Competition 2017 - Applications now open!
ventureLAB Launches Podcast
ventureLAB has started a monthly podcast featuring a topic relevant to entrepreneurs, intrapreneurs and the companies that want to work with them. From crowdfunding for equity to agile business planning, you'll hear from experts and entrepreneurs, and get the grass roots knowledge on what the ventureLAB innovation ecosystem is all about!
Ontario Genomics: Genomic Applications Partnership Program (GAPP)
The GAPP promotes the commercialization and translation of genomics-derived technologies. It provides a unique opportunity for User organizations to leverage their R&D investments with public funding. GAPP fosters academic collaborations with Users from industry, government, not-for-profits, and other organizations. Successful projects are driven by the User and focus on areas of opportunity that they have identified.
Ontario Genomics Report: Think Synthetic Biology in Ontario
Ontario Genomics is pleased to introduce this report on synthetic biology in Ontario.
Biology holds the key to all of humanity’s industrial, environmental and health challenges. What is left for us to do is pinpoint the right solutions from the genomes of millions of living organisms and put them to use in our factories, our hospitals and our homes.
Call for CTA@ Boston Applications Winter/Spring 2017 Program Placement - Deadline: October 13, 2016
Are you a Canadian IT, life sciences, robotics or foodtech company ready to grow and commercialize in the US market?
The Canadian Technology Accelerator in Boston is an award-winning 4-month immersion program that connects Canadian companies to US clients, strategic partners, and investors! Managed and operated by the Consulate General of Canada in Boston's Trade Commissioner Service team in close partnership with the CENE.
The Canadian Technology Accelerator in San Francisco - Life Sciences
KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC
October 3, 2016 – Montreal, QC, Toronto and Ottawa, ON ─ KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co-developing since 2015.
The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom-engineered therapeutic developed at NRC.
Synaptive Medical Completes First Installation of Revolutionary Brain Surgery Technology at Mount Sinai Health System in New York
September 20, 2016, New York — Synaptive Medical, a medical device company relentlessly pursuing connections to transform the process of care, has successfully installed their BrightMatter™ technology at Mount Sinai Health System in New York City. Mount Sinai, ranked #12 in the country by U.S. News & World Report for its neurology and neurosurgery program, is the first hospital in the New York Metropolitan area to acquire this revolutionary technology.
For the full press release, click here
New Study Provides Further Evidence that Rna Disruption Assay™ (RDA™) May Be Useful Tool In Predicting Clinical Outcome Of Chemotherapy In Breast Cancer Patients
Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute
A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients.
For the full press release, click here
For the Journal Article, click here
Medical Developments International Limited Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada
Sept 11, 2016 Medical Developments International Limited ("MDI") (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada.
Penthrox® is a fast-acting, inhaled, non-narcotic analgesic drug/device combination for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.
For the full press release, click here
Self Care Catalysts: App to Support Self-Management for Primary Biliary Cholangitis (PBC)
September 09, 2016 - Toronto: To celebrate International PBC Day on September 11, 2016, Self Care Catalysts -- a patient intelligence and solutions company -- is announcing its newest self-care mobile app, created to support patients diagnosed with Primary Biliary Cholangitis (PBC). The team at Self Care Catalysts worked closely with the Canadian PBC Society to create a customized suite of self-care tools to support the total care for PBC, and to empower patients to play an active role in tracking their health story -- so that more can be understood about this rare disease.
For the full press release, click here
100 Brains + 50 Locations = The Brain Project
100 brains, 50 locations all for 1 important cause: Brain Health!
The art installations can be found across Toronto and highlight the importance of brain health with the aim to improve the quality of life for those with dementia and other neurological disorders.
The project is being delivered by the Baycrest Foundation who see the project as a"catalyst for discussion and awareness of brain health."
Learn more here
Find a Brain Installation here